⚡
CHARGED ALPHA
Stock Detail
Stock Library / AMGN
AMGN Healthcare

Amgen Inc.

Live stock metrics, chart context, a quarter-by-quarter YouTube archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Company Website Back to Library

Library coverage

Quarters tracked
1
YouTube quarters live
0
Latest video
Pending
YouTube available
No
Current price
$355.30
+4.82 (+1.38%)
Trailing / Forward P/E
24.93x
Forward: 15.26x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
8.6%
Earnings: 112.1%
Margins
30.6% op
Gross: 70.8% · Net: 21.0%
Balance sheet
1.14x current
Debt / Equity: 640.3
52-week range / Beta
$261.43 - $391.29
Beta: 0.47
Analyst target
$352.03
Upside: -0.9%
Cash / shareholder return
3.92% FCF yield
Dividend yield: 2.72%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees: —
Price to book: 22.11x
Return on equity: 106.1%
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Price chart

Market context for AMGN

Competitive view

AMGN vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Amgen Inc.
AMGN
Latest video
YouTube link pending
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
UnitedHealth Group
UNH
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Merck & Co.
MRK
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
AMGN
$191.53B
Amgen Inc.
UNH
$294.66B
UnitedHealth Group
MRK
$294.39B
Merck & Co.
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
AMGN
24.9x
Amgen Inc.
UNH
24.5x
UnitedHealth Group
MRK
16.4x
Merck & Co.
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
AMGN
15.3x
Amgen Inc.
UNH
16.1x
UnitedHealth Group
MRK
12.2x
Merck & Co.
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
AMGN
8.6%
Amgen Inc.
UNH
12.3%
UnitedHealth Group
MRK
5.0%
Merck & Co.
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
AMGN
112.1%
Amgen Inc.
UNH
-99.9%
UnitedHealth Group
MRK
-19.3%
Merck & Co.
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
AMGN
30.6%
Amgen Inc.
UNH
0.3%
UnitedHealth Group
MRK
32.8%
Merck & Co.
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
AMGN
70.8%
Amgen Inc.
UNH
18.5%
UnitedHealth Group
MRK
77.2%
Merck & Co.
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
AMGN
21.0%
Amgen Inc.
UNH
2.7%
UnitedHealth Group
MRK
28.1%
Merck & Co.
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
AMGN
106.1%
Amgen Inc.
UNH
12.5%
UnitedHealth Group
MRK
36.9%
Merck & Co.
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
AMGN
3.9%
Amgen Inc.
UNH
4.7%
UnitedHealth Group
MRK
4.0%
Merck & Co.
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
AMGN
640.27x
Amgen Inc.
UNH
81.62x
UnitedHealth Group
MRK
95.96x
Merck & Co.
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
AMGN
1.14x
Amgen Inc.
UNH
0.79x
UnitedHealth Group
MRK
1.54x
Merck & Co.
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
AMGN
0.47
Amgen Inc.
UNH
0.41
UnitedHealth Group
MRK
0.28
Merck & Co.
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
AMGN
2.7%
Amgen Inc.
UNH
2.8%
UnitedHealth Group
MRK
2.8%
Merck & Co.
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
AMGN
-0.9%
Amgen Inc.
UNH
11.0%
UnitedHealth Group
MRK
9.0%
Merck & Co.

YouTube timeline

Quarterly archive for AMGN

Each row is one quarter. Only the YouTube link is shown here for now.

Q1 2026
Video pending
Pending link pending
Quarterly earnings-analysis entry for Amgen Inc.. Use the YouTube link on the right to jump straight into that quarter's video when it is live.
No verified YouTube link yet